|
Re: Todays FDA hearing on Avastin,news from Genentech..
There is a lot to suggest that time of day of dose can influence efficacy and toxicity of chemos. Studies at this point are probably giving doses according to convenience. Hrushesky feel sthat a tNF therapy was dismissed due to toxicity that could have been lessened by appropriate chronotherapy. so..amount of dosage and time of dosage may be wild cards in this process...only one of which is addressed by functional profiling.
|